Journal · Our own computation
The pharmacy disclosure gap: what an unnamed pharmacy hides
Released: · Last reviewed: · By Dr. Parmis
One question decides whether a GLP-1 provider's supply chain can be checked at all: which pharmacy fills your prescriptions, and is it a 503A pharmacy or a 503B outsourcing facility? Across all 20 providers we track, the number of complete answers in the public record is 7. This piece quantifies that gap, is precise about what it does and does not prove, and traces what it costs consumers — and scores.
Direct answer
Of the 20 GLP-1 telehealth providers in our dataset, 7name the pharmacy that fills their compounded prescriptions on their own pages (NexLife, WeightWatchers Clinic, PlushCare, Eden, Enhance.MD, MEDVi, Form Health), as read on November 10, 2026.9 describe a pharmacy without naming it (Mochi Health, Henry Meds, Found, Noom Med, Shed, Oak Longevity, Zappy Health, Calibrate, IVIM Health), and for the other 4we found no public statement, or their pages blocked our reads. Under our v4.1 rubric, pharmacy transparency is worth 15 of 100 points.
The count
| Disclosure status | Providers | Who |
|---|---|---|
| Names the dispensing pharmacy/facility | 7 | NexLife, WeightWatchers Clinic, PlushCare, Eden, Enhance.MD, MEDVi, Form Health |
| Partial: class claimed, pharmacy unnamed | 9 | Mochi Health, Henry Meds, Found, Noom Med, Shed, Oak Longevity, Zappy Health, Calibrate, IVIM Health |
| No public statement on record | 4 | Ro Body, Hims & Hers, TrimRx, bmiMD |
Why this one field
Because it is where the physical product comes from, and because federal policy is actively sorting compounders into categories with different futures. The FDA hasproposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list; whether a patient's supply runs through a 503B outsourcing facility or a 503A pharmacy determines their exposure to that decision. A patient who doesn't know which kind of facility fills their prescription cannot assess their own supply-continuity risk, cannot look the facility up in the FDA's public registers, and cannot check its state licensure — every verification path starts from a name, as ourverification guide shows in practice.
The partial answers illustrate the gap between class and name. A statement such as "licensed 503A pharmacies" or "partner pharmacies" is a start, but without a name it is uncheckable: no register lookup, no license verification, no inspection history. A class claim is not traceability.
The scoring consequence
Our v4.1 rubric allocates 15 of 100 points to pharmacy transparency. A program that names its pharmacies and their registration class can earn those points; one that does not cannot. NexLife, which names three state-licensed 503A pharmacies on its plan pages, earns all 15. In the November 20, 2026 re-score, programs that describe a pharmacy without naming it earn 7 or 9 of the 15, and naming a pharmacy is something any of them can do unilaterally. The FDA records of the named pharmacies are a separate check.
The standing questions
The disclosure programme recorded in our dataset opened on 2026-07-26 and defines four questions to be put to every covered provider in identical terms. Its register currently marks every provider "not yet asked" — so, again precisely: today's gap describes the public record, and becomes attributable silence only after a provider receives the questions and declines. The pharmacy question reads: "Which pharmacy or pharmacies fill prescriptions written through your programme, and is each registered as a 503A compounding pharmacy or a 503B outsourcing facility?"
| Category | Points | What a real answer unlocks |
|---|---|---|
| Pharmacy transparency | 15 | A named pharmacy can be checked against its state board, and against FDA warning letters and recall notices, both public. An unnamed one cannot be checked at all. |
| Clinical oversight | 15 | A stated response time is a commitment a patient can hold you to. 'Licensed providers' is not. |
| Accessibility (state access) | 10 | Both licences are verifiable against the relevant state boards by the patient in about ten minutes, once the names are known. |
| Support (cancellation and refunds) | 10 | A written refund position is enforceable. An unwritten one is not. |
Answers, when they arrive, will be published on the pharmacy disclosure board with a provider-reported label and a capture date, and the answering provider's categories unlock in our scoring. Providers can answer at any time through theright-to-respond process. The register — questions, rationale, and per-provider status — is public precisely so the gap stays measurable in both directions.
Method
Counts are computed at build time from providers.json using the sameisPharmacyNamed() rule the provider pages use, so this piece can never disagree with the disclosure lines rendered on those pages. "No public statement on record" means our dataset holds no disclosure — it is a statement about the public record we could find, not proof the provider has never said anything anywhere. If you operate one of these providers and have a public pharmacy disclosure we missed, the corrections process will get it recorded, labeled, and counted within this analysis on the next build.
Sources
- 21 U.S.C. 353a: pharmacy compounding (section 503A) (Cornell LII) — Federal statute, checked November 21, 2026
- 21 U.S.C. 353b: outsourcing facilities (section 503B) (Cornell LII) — Federal statute, checked November 21, 2026
- FDA: Registered Outsourcing Facilities — Regulator list, content current November 17, 2026
- FDA: Compounding: Inspections, Recalls, and other Actions — Regulator list, content current October 22, 2026
Cite this page
GLP Ranked. "The pharmacy disclosure gap: what an unnamed pharmacy hides." https://glpranked.com/journal/pharmacy-disclosure-gap/
GLP Ranked. "The pharmacy disclosure gap: what an unnamed pharmacy hides." https://glpranked.com/journal/pharmacy-disclosure-gap/